Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
11:25am, Friday, 12'th May 2023
Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 10'th May 2023
Adma Biologics (ADMA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.10 per share a year ago.
ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023
07:00am, Wednesday, 03'rd May 2023
RAMSEY, N.J. and BOCA RATON, Fla.
ADMA Biologics Announces Q4 And FY 2022 Results
02:01pm, Friday, 24'th Mar 2023
ADMA Biologics (NASDAQ: ADMA) has reported its Q4 and full-year 2022 financial results. These are the details.
ADMA Biologics, Inc. (ADMA) Q4 2022 Earnings Call Transcript
10:10pm, Thursday, 23'rd Mar 2023
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director of Business Development & Corporate Strategy Adam Gro
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
07:03pm, Thursday, 23'rd Mar 2023
Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
07:00am, Thursday, 16'th Mar 2023
Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET Conference Call Scheduled for March 23, 2023, at 4:30 p.m. ET
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
01:29pm, Thursday, 09'th Feb 2023 Zacks Investment Research
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down
09:48am, Thursday, 09'th Feb 2023
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues
01:43pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
12:00pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth
Sage and Biogen's NDA for Depression Drug Gets Priority Review
03:17pm, Tuesday, 07'th Feb 2023 Zacks Investment Research
Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod
06:27pm, Monday, 06'th Feb 2023 Zacks Investment Research
Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult pat
Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates
02:53pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.
Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up
04:27pm, Wednesday, 18'th Jan 2023 Zacks Investment Research
Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.69% in response.
